RhumbLine Advisers’s Kazia Therapeutics KZIA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.4K Sell
1,083
-213
-16% -$2.67K ﹤0.01% 3831
2026
Q2
$18.2K Sell
1,296
-106
-8% -$1.29K ﹤0.01% 3827
2026
Q1
$10.4K Sell
1,402
-163
-10% -$1.14K ﹤0.01% 3801
2025
Q4
$10.8K Buy
1,565
+974
+165% +$8.3K ﹤0.01% 3845
2025
Q3
$4.32K Hold
591
– – ﹤0.01% 3925
2025
Q2
$3.66K Buy
591
+209
+55% +$976 ﹤0.01% 3945
2025
Q1
$1.49K Sell
382
-174
-31% -$1.03K ﹤0.01% 4004
2024
Q4
$4.91K Hold
556
– – ﹤0.01% 3960
2024
Q3
$12K Buy
556
+204
+58% +$4.07K ﹤0.01% 3867
2024
Q2
$4.01K Buy
352
+109
+45% +$1.62K ﹤0.01% 4116
2024
Q1
$3.83K Buy
243
+49
+25% +$734 ﹤0.01% 4016
2023
Q4
$4.36K Buy
194
+43
+28% +$1.26K ﹤0.01% 4006
2023
Q3
$7.56K Hold
151
– – ﹤0.01% 3915
2023
Q2
$8.61K Buy
+151
New +$9.5K ﹤0.01% 3983

Other funds holding KZIA

RhumbLine Advisers's KZIA Position: Q3 2026 in Review

RhumbLine Advisers reduced its Kazia Therapeutics (KZIA) stake by 16% in Q3 2026, selling an estimated $2.67K and leaving 1,083 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3831.

RhumbLine Advisers first reported a position in KZIA in Q2 2023 and has held it in 14 quarters since. The position peaked at $18.2K in Q2 2026. 55 funds tracked by Wall St. Rank hold KZIA as of Q3 2026.

  • RhumbLine Advisers held 1,083 shares of Kazia Therapeutics worth $10.4K as of Q3 2026.
  • RhumbLine Advisers sold 213 Kazia Therapeutics shares in Q3 2026, an estimated $2.67K.
  • Kazia Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3831 holding.
  • RhumbLine Advisers first reported a position in Kazia Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • RhumbLine Advisers's Kazia Therapeutics position peaked at $18.2K in Q2 2026.
  • 55 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.